|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.415 USD | -2.81% |
|
-3.71% | -45.19% |
| Apr. 25 | Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa | CI |
| Apr. 15 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Soligenix, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 0.839359 million compared to USD 0.948911 million a year ago. Net loss was USD 6.14 million compared to USD 13.8 million a year ago.
Basic loss per share from continuing operations was USD 0.79 compared to USD 4.81 a year ago. Diluted loss per share from continuing operations was USD 0.79 compared to USD 4.81 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -45.19% | 5.91M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
SOLIGENIX, INC. 
